The stock rose as much as 8.6% in Copenhagen trading, clocking its biggest gain so far this year. That follows a decline of more than 20% last week, when the company warned that its sales will fall more than expected this year and Hims & Hers launched its cut-price drug before abruptly reversing course.
WATCH: Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill. Source: Bloomberg
Hims & Hers said it would stop ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
